Hypertension in pregnancy: diagnosis and management
KEYWORDS: women, hypertension, pre-eclampsia, pregnancy, treatment, birth, committee, recommendations, antihypertensive, amended, risk, blood, evidence, care, gestational

a short explanation of why the committee made the 2019 recommendations and how they might affect practice, see rationale and impact section on risk of recurrence of hypertensive disorders of pregnancy and long-term cardiovascular disease. Full details of the evidence and the committee's discussion are in evidence review F: advice at discharge. Body mass index and recurrence of hypertensive disorders of pregnancy 1.10.5 Advise women who have had pre-eclampsia to achieve and keep a BMI within the healthy range before their next pregnancy (18.5 to 24.9 kg/m2). See also the NICE guideline on overweight and obesity management. [2010, amended 2019] Inter-pregnancy interval and recurrence of hypertensive disorders of pregnancy 1.10.6 Advise women who have had pre-eclampsia that the likelihood of recurrence increases with an inter-pregnancy interval greater than 10 years. [2010, amended 2019] Long-term risk of end-stage kidney disease 1.10.7 Tell women with a history of pre-eclampsia who have no proteinuria and no hypertension at the postnatal review (6 to 8 weeks after the birth) that although the relative risk of end-stage kidney disease is increased, the absolute risk is low and no further follow-up is necessary. [2010] Thrombophilia and the risk of pre-eclampsia 1.10.8 Do not routinely perform screening
